Product Reports Resources Pricing Login Book a demo

Syros Pharmaceuticals

Biotech & Life Sciences · Watertown, United States · Founded 2012 · IPO 2016

Redefining the power of small molecules to control gene expression and to provide a profound benefit for patients MoreLess

Syros Pharmaceuticals is a biopharmaceutical company focused on developing innovative gene control medicines to treat cancer and genetic diseases. The company operates in the healthcare and biotechnology market, primarily serving patients with acute myeloid leukemia and select solid tumors. Syros' business model revolves around the research, development, and commercialization of small molecule therapies that precisely control gene expression. The company generates revenue through partnerships, licensing agreements, and potential future sales of its proprietary medicines. Syros is advancing a pipeline that includes two investigational medicines in clinical trials and multiple programs in preclinical development. The company's approach leverages its expertise in gene control to create targeted therapies that aim to transform patient outcomes.

Keywords: gene control, small molecules, cancer therapy, genetic diseases, biopharmaceutical, acute myeloid leukemia, solid tumors, clinical trials, biotechnology, innovative medicines.

Valuation $2.0M
Revenue $9.9M
Total funding $100–500M

Talent graph

Syros Pharmaceuticals's talent

Book a demo to see the people
Team profiled 26 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

20 investors on Syros Pharmaceuticals's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 6 investors entered at this stage
Flagship Pioneering
ARCH Venture Partners
Redmile Group
WuXi Healthcare Ventures
Polaris Partners
Aisling Capital
Series B+ 14 investors entered at this stage
Deerfield
Oxford Finance
Bain Capital
Bain Capital Life Sciences
Ally Bridge Group
Samsara BioCapital
Omega Funds
EcoR1 Capital
OrbiMed
Adage Capital
Invus
Dafna Capital Management
Deep Track Capital
Blue Owl Capital

Global footprint

Where Syros Pharmaceuticals has talent and traffic

Workforce by country
🇺🇸 United States · Watertown HQ
Book a demo for the full country breakdown

Market sentiment

What the market is saying about Syros Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Syros Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Syros Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.